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PCardiovascular Therapies
and Associated Glucose Homeostasis
Implications Across the Dysglycemia Continuum
Rhonda M. Cooper-DeHoff, PHARMD, MS,* Michael A. Pacanowski, PHARMD, MPH,†
Carl J. Pepine, MD, MACC*
Gainesville, Florida
Certain cardiovascular drugs have adverse effects on glucose homeostasis, which may lead to important
long-term implications for increased risks of adverse outcomes. Thiazide diuretics, niacin, and beta-
adrenergic blockers impair glucose homeostasis. However, angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers have demonstrated beneficial metabolic effects. The newer vasodilating beta-
blocking agents and calcium antagonists appear to be metabolically neutral. These considerations, in addi-
tion to meticulous attention to blood pressure control and lifestyle changes, have the potential to benefi-
cially modify glycemia and long-term risks. These considerations have particular importance in younger
patients who may also have pre-diabetes or the metabolic syndrome and who are likely to require therapy
over the course of decades. (J Am Coll Cardiol 2009;53:S28–34) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.037t
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iiabetes is a leading cause of cardiovascular (CV) morbidity
nd mortality worldwide, and in the U.S. it is associated with
n estimated cost of $174 billion annually (1). Patients with
iabetes have increased risk for coronary heart disease (CHD),
HD-related death, and stroke compared with those without
iabetes (2). Among those with established CHD, the risk for
dverse outcomes (e.g., death, myocardial infarction, or stroke)
ncreases approximately 2- to 4-fold (3,4). Characteristics of
atients at risk for developing diabetes include race, ethnicity,
ncreased body mass index, left ventricular hypertrophy, stroke,
nd elevated blood pressure (BP) (5–7). It is now increasingly
ecognized that dysmetabolic states, such as metabolic syn-
rome (MetSyn), especially when elevated glucose is present,
lso increase CV risk, although as will be discussed, to a lesser
xtent than diabetes. These states often progress to diabetes.
ndeed, hypertension, diabetes, and coronary artery disease
CAD), both diagnosed and undiagnosed, frequently coexist,
articularly when the diagnoses are broadened to include
re-hypertension, atherosclerosis, and pre-diabetes (Fig. 1).
re-diabetes was introduced not only in the hopes of making
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ccepted October 28, 2008.he concepts of impaired fasting glucose (IFG) and impaired
lucose tolerance (IGT) more understandable to the lay audi-
nce, but also in the hope that increased attention to the
onsequences of diabetes could perhaps forestall its develop-
ent. Ultimately, however, the concept of pre-diabetes must
elate to identification and management of patients at risk for
HD.
oncept of Pre-Diabetes
re-diabetes is a relatively common condition characterized by
ither IFG (fasting plasma glucose of 100 to 125 mg/dl) or
GT (2-h plasma glucose of 140 to 199 mg/dl after a 75-g
lucose load) (8). Among U.S. adults ages 40 to 74 years
etween 1988 and 1994, approximately 15% had IGT and
pproximately 34% had IFG. Projecting these rates onto the
otal U.S. population in 2007, an estimated 54 million adults
ave pre-diabetes (9), which is an approximate increase of10
illion people since 2000 (10).
Impaired fasting glucose is a component of MetSyn, which
s a constellation of risk factors including abdominal adiposity,
yperglycemia, hypertension, and dyslipidemia (11). The risk
f developing diabetes is increased 3- to 5-fold when MetSyn
s present (12), and CV disease risk in patients with MetSyn is
ncreased 1.5- to 3.5-fold compared with those without MetSyn
13,14). Hyperinsulinemia and insulin resistance, defined as a
ailure of target organs to respond normally to insulin, may be
mportant in the pathogenesis of, and often coexist with,
ypertension, obesity, and diabetes (15,16). The prevalence of
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February 3, 2009:S28–34 CV Therapy and Glucose HomeostasisetSyn is estimated at 25% in the U.S., and prevalence
ncreases with age. In people age 20 to 29 years, the prevalence
as 6.7% compared with people age 60 to 69 years, in whom
he prevalence was 43.5% (17).
At the vascular wall level, hyperglycemia decreases the
ioavailability of nitric oxide and prostaglandin I2 and
ncreases synthesis of vasoconstrictor prostanoids and endo-
helin via multiple mechanisms (18). The resultant vascular
ysfunction has important functional and structural conse-
uences as discussed elsewhere in this supplement. There is
ontroversy regarding the degree to which pre-diabetes
lone increases CV risk. There are data indicating no
ncrease in CV risk associated with either IFG or IGT (19)
nd data that suggest the CV risk associated with pre-
iabetes is lower than that associated with diabetes (20,21).
owever, many studies indicate that like diabetes, pre-
iabetes (alone or in combination with MetSyn) is associ-
ted with a significant increase in CV morbidity and
ortality (22–25). These controversial findings may relate
o varying levels of risk in the cohorts followed, as well as
arying follow-up durations.
Unfortunately, many drugs used in the management of
V disease or its risk conditions can affect glucose and lipid
omeostasis, and insulin resistance is an important mediator
f these metabolic effects. Although length of follow-up and
xact metabolic outcome in many of the reports vary, the
esults are consistent. For instance, diuretics, beta-blockers,
nd niacin have adverse metabolic effects that may precip-
tate diabetes development in those with pre-diabetes, but
he renin-angiotensin-aldosterone system (RAAS) antago-
Figure 1 Cardiovascular Disease: Coincidence of
Hypertension, Coronary Artery Disease, and Diabetes
Inner circles and outer circles represent diagnosed and undiagnosed hyperten-
sion, coronary artery disease, and diabetes, respectively. Areas and their over-
laps are roughly proportional to estimated prevalence of these conditions in
the U.S. population. The larger outer area represents incidence of metabolic
syndrome, which includes pre-hypertension, pre-diabetes, and dyslipidemia.
Data from the American Heart Association (2) and the Centers for Disease
Control and Prevention (10).eists may have beneficial effects
hat may delay or prevent the
evelopment of diabetes. A recent
etwork meta-analysis of hyper-
ension clinical trials ranked the
ssociation of antihypertensive
gents with incident diabetes as
owest for angiotensin-converting
nzyme (ACE) inhibitors and
ngiotensin receptor blockers
ARBs), followed by calcium an-
agonists, which appear neutral,
nd highest for beta-blockers and
iuretics (26). There was no sig-
ificant difference in the odds ratio
or diabetes development compar-
ng diuretics and beta-blockers
26). The presence of diabetes or
re-diabetes, especially in the pres-
nce of the risk factors associated
ith MetSyn, should be consid-
red when choosing CV therapies.
V Agents With Unfavorable Metabolic Effects
hiazide diuretics. Thiazide diuretics have been available
or the treatment of hypertension since the late 1950s, and
eports of thiazide-associated hyperglycemia began appear-
ng shortly thereafter (27,28). However, benzothiadiazine
erivatives (hydrochlorothiazide most commonly) continue
o be recommended as first-line therapy for hypertension
ithout regard to metabolic status (29). The American
iabetes Association, in its recently published standards,
uggests treatment of hypertension and other CV disease
isk factors to prevent and/or delay type 2 diabetes, but
akes no mention of which antihypertensive agents should
e preferentially used (8). Data from a number of large
ypertensive treatment trials, as well as epidemiologic data
rom large cohort studies, have associated a new diagnosis of
iabetes with hypertension treatment that contains a thia-
ide diuretic, including chlorthalidone (30,31), hydrochlo-
othiazide (32,33), and bendroflumethiazide (34). Although
here is not uniform agreement on the long-term signifi-
ance of diuretic-induced diabetes (35), the controversy
eems more about the relative benefits from improved BP
ontrol offset by the consequences of worsening metabolic
tatus related to the thiazide diuretic. Data from ALLHAT
Antihypertensive and Lipid-Lowering Treatment to
revent Heart Attack Trial) study suggest there may
e no increased risk for CV outcomes in those with
hlorthalidone-induced dysglycemia or diabetes (36). How-
ver, lack of documented increased risk for adverse out-
omes is not the same as proof that risk for adverse
utcomes is not increased with thiazides. In many situa-
ions, their effective reduction in BP and favorable adher-
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blocker
BP  blood pressure
CAD  coronary artery
disease
CHD  coronary heart
disease
CV  cardiovascular
HDL-C  high-density
lipoprotein cholesterol
IFG  impaired fasting
glucose
IGT  impaired glucose
tolerance
MetSyn  metabolic
syndrome
RAAS  renin-angiotensin-
aldosterone systemnce profile likely obscured such adverse effects. Also, the
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CV Therapy and Glucose Homeostasis February 3, 2009:S28–34ailure of increased risk to emerge may be related to the
elatively short follow-up period (37) and lack of power to
etect a difference in outcomes in this subset of patients,
ecause ALLHAT was not designed a priori to make this
omparison (33,38). Indeed, less than one-quarter of the
atients had a fasting glucose measured during follow-up
nd the patient sample used for this analysis included 3
imes more patients taking chlorthalidone than the ACE
nhibitor, with only about 3 years of follow-up. In patients
ollowed for 15 years, diabetes associated with diuretic use
as linked with significant CV risk (32). Recent data add to
he growing evidence documenting additional adverse out-
omes (e.g., heart failure and atrial fibrillation) related to
ncident diabetes associated with use of antihypertensive
egimens containing a diuretic and/or beta-blocker (39).
Although the mechanism of thiazide-induced glucose
levation may not have been well understood in the late
950s, a significant inverse relationship between potassium
nd glucose levels in which lower blood potassium levels are
ssociated with higher glucose values has been documented
40). There is an association between hypokalemia and
mpaired insulin secretion that may partially explain this
nverse relation (41), but this is unlikely to be the only
echanism. Although it has been suggested (40,42) that
aintenance of potassium homeostasis by supplementation
r concomitant use of an ACE inhibitor or ARB may
educe or prevent the glucose increases associated with
hiazide diuretics, this has not been prospectively evaluated
n patients with pre-diabetes or MetSyn. We have observed
hat an ACE inhibitor is protective in hypertensive CAD
atients taking a calcium antagonist but not a beta-blocker
lus diuretic at low or moderate doses (Fig. 2) (6). Impor-
Figure 2 Risk of Diabetes by Base- and Added-Strategy Drug D
Reference (hazard ratio [HR]: 1.0)  atenolol 50-mg/day monotherapy. Data from
(International Verapamil SR-Trandolapril Study) trial (6). CI  confidence interval; Hantly, it is not known if potassium supplementation
odifies the increased risk for diabetes associated with
hiazide diuretics. To this end, the National Heart, Lung,
nd Blood Institute has constituted a working group to
evelop a clinical trial initiative to better elucidate the
elationship between glucose, potassium, and thiazide-
nduced diabetes (41).
A main concern of CV specialists is the use of agents that
ave a negative impact on glucose homeostasis in hyperten-
ive and/or other vascular disease patients, who may also
ave pre-diabetes or MetSyn. This concern is most relevant
hen these patients are relatively young, have a lengthy life
xpectancy, and perhaps may be most susceptible to wors-
ning glucose tolerance secondary to diuretics. These pa-
ients are likely to receive thiazide diuretics for decades, and
he implications of diuretic-induced diabetes may not be
ully understood in the relatively short-term clinical trial
ata available to date (43). When a thiazide diuretic is
equired for BP reduction, close attention should be paid to
lucose homeostasis, with recognition that pharmacologic
anagement of glucose may be required (44).
eta-blockers. Beta-adrenergic blockers have also long
een recommended as first-line therapy for the treatment of
ypertension (29) and CAD. However, like thiazide diuret-
cs, beta-blockers have been implicated in altering glucose
omeostasis, primarily through inhibition of pancreatic
nsulin secretion and promoting insulin resistance (45,46).
eta-receptor selectivity appears to play a role in the degree
f downstream metabolic effects, which include not only
lucose increases but also weight gain and dyslipidemia.
lthough nonselective and higher-dose selective agents
esult in the largest adverse metabolic changes (47), vaso-
n Hypertensive Coronary Artery Disease Patients
VEST
hydrochlorothiazide; SR  sustained release.ose i
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February 3, 2009:S28–34 CV Therapy and Glucose Homeostasisilating beta-blockers (e.g., nebivolol and carvedilol) appear
o minimally affect glucose homeostasis and improve insulin
ensitivity (47–49). These adverse metabolic effects, in
ombination with limited data supporting beneficial anti-
ypertensive effects of beta-blockers as first-line or mono-
herapy for uncomplicated hypertension, have led to the
uggestion that beta-blockers be reserved for the treatment
f complicated hypertension, heart failure, arrhythmia, and
ost-myocardial infarction patients (50).
A recent meta-analysis of beta-blockers and new-onset
iabetes in almost 95,000 patients (51) and a network
eta-analysis in over 143,000 patients (26) from hyperten-
ion trials document the relative diabetogenic effect of
eta-blockers when given alone or with other agents, which
s often the case among patients with CV disease. In both
nalyses, beta-blockers were similarly diabetogenic com-
ared with thiazide diuretics and much more so compared
ith ACE inhibitors, ARBs, which were beneficial in this
egard, and calcium antagonists, which were neutral.
iacin. Hypertensive, MetSyn, and CAD patients often
ave reduced high-density lipoprotein cholesterol (HDL-
), and former guidelines for the care of these patients
ncluded niacin (nicotinic acid) in the hope that it may
educe morbidity and mortality by raising HDL-C (22).
owever, in current guidelines, niacin is only recommended
or reduction of triglycerides 500 mg/dl or as a last resort
or reducing non–HDL-C (52). Niacin’s action on insulin
esistance, dysglycemia, and diabetes control is very potent
nd well recognized (53). Although beneficial effects of
iacin on lipids have been shown in populations with
etSyn, diabetes, and atherosclerosis (54,55), worsening
lycemic control remains a concern over the long term and
odifications in antidiabetic medications will likely be
ecessary to maintain adequate glucose control. Among
articipants in the HATS (HDL-Atherosclerosis Treat-
ent Study) trial without diabetes or IFG at baseline, 2.4%
nd 9.7% developed diabetes and IFG, respectively, during
he study, although this was not statistically significant (56).
lthough niacin has been shown to be beneficial in post-
yocardial infarction patients (57), in the absence of ath-
rosclerotic CV disease, documented benefits of HDL-C
aising with niacin are lacking; thus niacin should not be
sed in patients with MetSyn but without atherosclerosis.
V Agents With Favorable Metabolic Effects
AAS antagonists. The RAAS has been implicated in
lucose and insulin regulatory pathways (25,58), and inhi-
ition of the RAAS by ACE inhibitors and ARBs has been
ssociated with prevention of diabetes in many randomized
rials of hypertensive, heart failure, and high-risk patients
33,59,60). These data prompted the DREAM (Diabetes
eduction Assessment with Ramipril and Rosiglitazone
edication) study, a clinical trial of diabetes prevention
ith ramipril. In 5,000 MetSyn patients followed for 3
ears, almost three-quarters of whom had pre-diabetes at raseline (either IFG [28%], IGT [57%], or both [28%]),
reatment with ramipril was associated with a significant
ncrease in regression to normoglycemia, although ramipril
id not significantly reduce the incidence of new diabetes
61). Because the DREAM study was stopped early, the
-year follow-up period may have been insufficient time to
etect a significant difference in the already developing
rend of new-onset diabetes reduction observed.
Direct renin inhibitors, the newest agents in the RAAS
ntagonist class of medications, are effective alone and in
ombination with either ACE inhibitors or ARBs for BP
owering in those with and without diabetes. However,
here are no published data at this time indicating their
ffects on glucose and insulin regulatory pathways, or on
iabetes prevention.
Recently, aldosterone has been implicated in the insulin
egulatory pathway, impairing insulin signaling by down-
egulating insulin receptor substrate-1 in vascular smooth
uscle cells (62). Local aldosterone has also been implicated
n worsening vascular disease. Whether there is a causal
elationship between aldosterone and insulin resistance
nd/or hyperinsulinemia is unclear, but there is evidence
hat aldosterone may worsen pre-existing alterations in
lucose homeostasis, as in those with MetSyn (63). Al-
hough there are currently limited data evaluating the effects
f aldosterone blockade on glucose or insulin homeostasis,
se of aldosterone antagonists for the treatment of resistant
ypertension in patients with pre-diabetes or MetSyn may
e beneficial. The mild diuretic effect of spironolactone may
e useful to avoid the need for hydrochlorothiazide or to
elp reduce the dose of hydrochlorothiazide. More research
s needed to better understand the role of these agents in
mproving glucose homeostasis.
ntianginal agents. Diabetes is a frequent comorbidity in
atients with CAD, many of whom also have chronic stable
ngina and at least one-half of these angina patients have
ess than optimal BP control. In a cohort of 22,000 CAD
atients followed for about 3 years, presence of diabetes
ndependently predicted an almost doubling (14.3% vs.
.4%) in the rate of death, nonfatal myocardial infarction, or
onfatal stroke (3). Although use of multiple antidiabetic
gents is common in diabetes patients with CAD and
hronic angina, diabetes control is often lacking.
The short- and long-term metabolic effects of ranolazine,
late sodium current blocker antianginal agent, have re-
ently been explored. After 12 weeks of ranolazine (750 or
,000 mg) daily in patients with diabetes and chronic
ngina, glycated hemoglobin levels were significantly re-
uced while fasting glucose and lipids remained unchanged
rom baseline (64). In the diabetic cohort of another
anolazine study in patients with acute coronary syndromes
ith average follow-up of 1 year (65), treatment with
anolazine was again associated with significant improve-
ent in glycated hemoglobin. In the nondiabetic cohort,
he incidence of an increased fasting glucose value was
educed (66). The beneficial antianginal and metabolic
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CV Therapy and Glucose Homeostasis February 3, 2009:S28–34ffects, in patients with and without diabetes, achieved with
anolazine suggest that this agent is a good choice for CAD
atients with diabetes or at risk for diabetes (67). These data
esulted in a recent change in FDA-approved labeling for
anolazine, with the inclusion of the statement “. . . pro-
uces small reductions in HbA1c in patients with diabetes,
he clinical significance of which is unknown, . . . should
ot be considered a treatment for diabetes.” The mechanism
f this benefit is also unclear, but in vitro and animal studies
uggest ranolazine may increase glucose-stimulated insulin
ecretion and this may be responsible for the improved
lucose homeostasis observed (68).
ther agents. Moxonidine is a selective imidazole II-
eceptor agonist that lowers BP by a central mechanism but
lso has been shown to have dose-dependent metabolic
ffects including reduction in glucose, insulin, and glycated
emoglobin in those with diabetes and MetSyn (69,70).
onclusions
he prevalence of pre-diabetes and diabetes continues to
ncrease, driven largely by obesity and physical inactivity.
ecause of the CV consequences of these conditions,
ttention to drugs that may worsen dysglycemia is impor-
ant. The European Society for Hypertension/European
ociety of Cardiology are no longer endorsing thiazide
iuretics or beta-blockers in hypertensive patients with
iabetes (71) and the American Association of Clinical
ndocrinologists recommends thiazide diuretic use only at
ow dosage and only with adequate potassium replacement
nd beta-blocker use only as second- or third-line agents in
atients with diabetes (72). The National Institute for
ealth and Clinical Excellence, together with the British
ypertension Society, recently published guidelines that
ndicate beta-blockers are no longer a suitable first-line
reatment option in uncomplicated hypertensive patients
argely due to increased incident diabetes (73). They also
ecommend use of RAAS inhibitors as first-line therapy in
ounger patients, with diuretics reserved for the elderly or
lack patients of any age (73). While thiazide diuretics
emain an inexpensive antihypertensive choice, the long-
erm costs of diabetes that may result far outweigh the
hort-term medication cost savings.
While BP control in patients with diabetes is important
or prevention of CV outcomes (74), BP control is also
mportant for lowering risk of diabetes development. Ob-
ervational data indicate that on-treatment systolic BP is an
mportant independent predictor of incident diabetes (32),
nd we confirmed this in a randomized clinical trial (Fig. 3)
6). For patients in whom BP control is difficult, especially
iabetics, thiazide diuretics and beta-blockers remain a
ecessary antihypertensive option; however, they should be
sed at as low a dose as possible and in combination with
ther antihypertensives. For patients with a recent myocar-
ial infarction, heart failure, or refractory angina, beta-
lockers remain a treatment of first choice; however, met-bolic status should be monitored closely in patients with
iabetes and at risk for diabetes.
With the exception of perindopril, all of the ACE
nhibitors approved for use in the U.S. are now available in
generic formulation, making them both cost-effective and
etabolically beneficial alternative antihypertensive agents.
hile generic lisinopril ranked number 2 with 62 million
rescriptions, generic hydrochlorothiazide and atenolol
anked 5 and 7 in the list of the top 200 generic drugs
rescribed in the U.S. for 2007, totaling 46 million and 42
illion prescriptions, respectively (75).
Those with dysglycemia are likely destined to head down
he path of diabetes development. Early identification of
oincident hypertension and dyslipidemia is imperative. Treat-
ent consideration should be given not only to the immediate
ffects of BP or angina reduction, but also to the longer term
mplications the medications have on the tenuous metabolic
athways across the dysglycemia continuum.
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